AxoGen

AXGN · NASDAQ

$36.17+$0.93 (+2.64%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $35.24

AXGN analyst rating

BuyConsensus of 12 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy12
Hold0
Underperform0
Sell0

12-month price target · 12 analysts

Average $54.77 (+51.4% upside)

Low: $48.48
Now: $36.17
High: $60.90

Upgrades and downgrades

The latest rating actions, newest first

AXGN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
B of A Securities	Oct 12, 2026	Initiates	Buy	$52.00	45%
Barclays	Oct 7, 2026	Initiates	Overweight	$55.00	—
Truist Securities	Oct 1, 2026	Maintains	Buy	$60.00 → $53.00	33%
Raymond James	Sep 25, 2026	Maintains	Outperform	$48.00 → $53.00	54%
Truist Securities	Aug 26, 2026	Initiates	Buy	$60.00	33%
Canaccord Genuity	Jul 30, 2026	Maintains	Buy	$50.00 → $55.00	38%
Citizens	Jul 30, 2026	Maintains	Market Outperform	$50.00 → $55.00	42%
HC Wainwright & Co.	Jul 30, 2026	Maintains	Buy	$50.00 → $53.00	40%
Canaccord Genuity	Apr 29, 2026	Maintains	Buy	$45.00 → $50.00	38%
Citizens	Apr 29, 2026	Maintains	Market Outperform	$42.00 → $50.00	42%

The case for and against

Updated Oct 16, 2026

Bull case

Axogen is viewed positively because its differentiated nerve-repair portfolio, led by Avance, has strong clinical validation, a 12-year competitive moat through Dec 2037, and expanding reimbursement coverage that should support wider adoption across underpenetrated markets. Surgeon feedback on Nerve Tape was favorable, citing large OR-time savings versus microsutures and meaningful workflow advantages, while the product could broaden procedure adoption and still remain additive even with some Axoguard cannibalization. Fundamentally, the company is also showing strong operating leverage, with 1Q26 sales of $61.5 million (+26.6% y/y), adjusted EBITDA of $5.7 million, cash of $103.6 million, no debt, and management guiding to at least 20% revenue growth and full-year free cash flow positivity.

Bear case

Axogen is facing a negative outlook because its growth depends heavily on Avance penetration, yet end-market adoption could stall while reimbursement remains uncertain in areas such as radical prostatectomy and broader payer coverage is still incomplete. Margin expansion also looks fragile: Avance now represents about 63% of YTD revenue, but longer-length graft mix, higher COGS, and the step-up in production costs tied to a biologic quality system are pressuring gross margins even as 2026 Adj. EBITDA is only $35M at a 12.5% margin. At the same time, higher sales-force investment and possible weaker rep productivity could limit operating leverage, and the company may still require additional financing before reaching profitability, creating dilution risk for shareholders.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.